ArticleKidney international2017
Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.
Article in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial.JAMA network open · 2026Trial
- Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.Journal of the American Society of Nephrology : JASN · 2018Trial
- Genetic kidney diseases: Decoding molecular taxonomies to drive precision nephrology and therapeutic innovation.Genes & diseases · 2027Review
- Blood pressure andClinical kidney journal · 2026Article
- Article
- Consistency of metabolite associations with measured glomerular filtration rate in children and adults.Clinical kidney journal · 2024Article
- Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.Kidney medicine · 2023Article
- Article
- Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.Contemporary clinical trials · 2022Article
- Multi-Institutional Implementation of Clinical Decision Support forJournal of personalized medicine · 2021Article
- Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Article
- Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease.Journal of the American Heart Association · 2019Observational
- You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease.Journal of the American Society of Nephrology : JASN · 2019Article
- Estimated glomerular filtration rate predicts incident stroke among Ghanaians with diabetes and hypertension.Journal of the neurological sciences · 2019Article
- Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.American journal of nephrology · 2019Article
- Article
- Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Article
- Diversity and inclusion in genomic research: why the uneven progress?Journal of community genetics · 2017Article
- APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
Although APOL1 high-risk genotype partially accounts for the increased susceptibility of blacks to chronic kidney disease (CKD), whether APOL1 associates differentially with mortality risk remains controversial. Here we evaluate the association between APOL1 genotype and risk of death and determine whether APOL1 status modifies the association between strict versus usual blood pressure control and mortality risk. We performed a retrospective analysis of the African American Study of Kidney Disease and Hypertension trial that randomized black participants with CKD to strict versus usual blood pressure control from 1995 to 2001. This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial. During a median follow-up of 14.5 years, risk of death did not differ between individuals with high- versus low-risk APOL1 genotypes (unadjusted hazard ratio 1.00 [95% confidence interval 0.76-1.33]). However, a significant interaction was detected between the APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, the risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, the risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]). Thus, strict blood pressure control during CKD associates with a lower risk of death in blacks with the high-risk CKD APOL1 genotype. Knowledge of APOL1 status could inform selection of blood pressure treatment targets in black CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.